Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Antiarrhythmic Therapy Versus Catheter Ablation as First Line Treatment for AICD Shock Prevention: A Randomized Vanguard Pilot Trial

NCT02114528 is registered in ClinicalTrials.gov with Ottawa Heart Institute Research Corporation as lead sponsor.

NCT NCT02114528
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02114528 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Antiarrhythmic Therapy Versus Catheter Ablation as First Line Treatment for AICD Shock Prevention: A Randomized Vanguard Pilot Trial
Lead sponsor
Ottawa Heart Institute Research Corporation
Phase
Phase 4
Overall status
Terminated
Start date
October 31, 2014
Completion date
November 30, 2015
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ventricular arrhythmia, ventricular tachycardia